Scholars Central

ArticlePublished 29 Feb 2024

Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Treatment Reduces the Declining Speed of Kidney Function in Patients with CKD Stage G5 Diabetic Nephropathy

Authors: Hiroyuki Terawaki, Takafumi Ito

Journal of Interventional Nephrology

Volume 7 · Issue 1 · Pages 205–208

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Here we report our experience with respect to the prescription of the Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) luseogliflozin in patients with CKD stage G5 Diabetic Nephropathy (DN). A total of 5 patients with DN with severe kidney dysfunction estimated Glomerular Filtration Rate (GFR); 6.18-14.82 mL/min/1.73 m2 prescribed luseogliflozin (2.5 mg/day) in addition to the already prescribed drug. After that, the declining speed of GFR (mL/min/1.73 m2/year) decreased in all cases, from -9.03 ± 10.43 to -2.28 ± 0.73, and the degree of reduction was correlated with the declining speed of GFR before treatment. All patients were able to select their preferred modality of Kidney Replacement Therapy (KRT) through a shared decision-making process before starting KRT. We believe that the use of the SGLT2i is beneficial for patients with DN even in CKD stage G5.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Interventional Nephrology
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Hiroyuki Terawaki”
  • BylineArticles whose byline prints “Takafumi Ito”